Not Yet RecruitingPhase 1/2

Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer

20 participantsStarted 2026-04

Plain-language summary

By doing this study, it is the hope to learn whether an injection of the measles, mumps, rubella (MMR) vaccine developed by Merck \& Co. (Merck's M-M-R® II) into the tumor is safe and effective in making the tumor smaller.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Age ≥ 18 years.
✓. Pathologically proven locally advanced adenocarcinoma of pancreas.
✓. Borderline resectable pancreatic cancer that is determined to be unresectable following completion of SoC chemotherapy and RT as evidenced by any of the following:
✓. Encasement of gastroduodenal artery up to the common hepatic artery/short segment encasement or abutment of the hepatic artery, but without extension to the celiac trunk.
✓. Venous involvement of SMV or portal vein, less than 180 degrees.
✓. Tumor abutment of SMA, less than half the circumference of the vessel wall. OR
✓. Greater than 180-degree encasement or occlusion/thrombus of SMA, unresectable SMV, or SMV-portal confluence occlusion.
✓. Direct involvement of inferior vena cava, aorta, celiac trunk, or hepatic artery, as defined by the absence of fat plane between low-density tumor and these structures on CT scan.

Exclusion criteria

✕. Pancreatic cancer that was either resectable before SoC treatment or became resectable following SoC chemotherapy and RT.
✕. Subjects with radiographically proven metastatic disease are excluded.
✕. Subject must not be pregnant and/or currently breastfeeding or plan to be.
✕. Subject must not have received any live vaccine, including MMR, within 30 days prior to the dose of study drug.
✕. Subject must not have treatment with any anti-cancer therapy including chemotherapy, radiotherapy, biological, immunotherapy or an investigational therapy, including targeted small molecule agents, within 5 half-lives (or 2 weeks if half-life is unknown) prior to day 1.
✕. Subject has no unresolved toxicities, AEs ≥ Grade 2 (NCI CTCAE version 5.0), from prior anticancer therapy.
✕. Any other condition that, in the opinion of the investigator, might interfere with the safe conduct of the study.

What they're measuring

Intratumoral T-Cell Response

Timeframe: Baseline to 4 weeks post injection

Trial details

NCT IDNCT07539155

SponsorUniversity of Arkansas

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2028-03

Contact for this trial

Joseph Holley, BS

501-214-2499 JAHolley@uams.edu

View on ClinicalTrials.gov More Borderline Resectable/Unresectable Pancreatic Cancer trials